{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:47:28Z","timestamp":1781758048161,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00192-021-04691-4","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T13:01:55Z","timestamp":1613739715000},"page":"703-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0578-003X","authenticated-orcid":false,"given":"Sarah E.","family":"Eckhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Handler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tenggardjaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tajnoos","family":"Yazdany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"4691_CR1","first-page":"513","volume-title":"Urogynecology and reconstructive pelvic surgery","author":"M South","year":"2015","unstructured":"South M, Karram M. Overactive bladder syndrome and nocturia. In: Walters M, Karram M, editors. Urogynecology and reconstructive pelvic surgery. Philadelphia: Saunders; 2015. p. 513\u20135."},{"issue":"6","key":"4691_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336. https:\/\/doi.org\/10.1007\/s00345-002-0301-4.","journal-title":"World J Urol"},{"issue":"2","key":"4691_CR3","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.juro.2006.09.045","volume":"177","author":"SS Harris","year":"2007","unstructured":"Harris SS, Link CL, Tennstedt SL, Kusek JW, McKinlay JB. Care seeking and treatment for urinary incontinence in a diverse population. J Urol. 2007;177(2):680\u20134. https:\/\/doi.org\/10.1016\/j.juro.2006.09.045.","journal-title":"J Urol"},{"issue":"3 Pt 1","key":"4691_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/00005392-200009010-00018","volume":"164","author":"B Schurch","year":"2000","unstructured":"Schurch B, St\u00f6hrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692\u20137. https:\/\/doi.org\/10.1097\/00005392-200009010-00018.","journal-title":"J Urol"},{"issue":"1","key":"4691_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","volume":"180","author":"L Brubaker","year":"2008","unstructured":"Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217\u201322. https:\/\/doi.org\/10.1016\/j.juro.2008.03.028.","journal-title":"J Urol"},{"issue":"6","key":"4691_CR6","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","volume":"177","author":"A Sahai","year":"2007","unstructured":"Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231\u20136. https:\/\/doi.org\/10.1016\/j.juro.2007.01.130.","journal-title":"J Urol"},{"issue":"1","key":"4691_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cct.2011.09.019","volume":"33","author":"AG Visco","year":"2012","unstructured":"Visco AG, Brubaker L, Richter HE, et al. Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial. Contemp Clin Trials. 2012;33(1):184\u201396. https:\/\/doi.org\/10.1016\/j.cct.2011.09.019.","journal-title":"Contemp Clin Trials"},{"issue":"13","key":"4691_CR8","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1001\/jama.2016.14617","volume":"316","author":"CL Amundsen","year":"2016","unstructured":"Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366\u201374. https:\/\/doi.org\/10.1001\/jama.2016.14617.","journal-title":"JAMA"},{"issue":"2","key":"4691_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/0974-7796.82170","volume":"3","author":"W Altaweel","year":"2011","unstructured":"Altaweel W, Mokhtar A, Rabah DM. Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder. Urol Ann. 2011;3(2):66\u201370. https:\/\/doi.org\/10.4103\/0974-7796.82170.","journal-title":"Urol Ann"},{"issue":"2","key":"4691_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249\u201356. https:\/\/doi.org\/10.1016\/j.eururo.2013.04.001.","journal-title":"Eur Urol"},{"issue":"3","key":"4691_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","volume":"61","author":"P Denys","year":"2012","unstructured":"Denys P, Le Normand L, Ghout I, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61(3):520\u20139.","journal-title":"Eur Urol"},{"issue":"6","key":"4691_CR12","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","volume":"184","author":"R Dmochowski","year":"2010","unstructured":"Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416\u201322. https:\/\/doi.org\/10.1016\/j.juro.2010.08.021.","journal-title":"J Urol"},{"issue":"6","key":"4691_CR13","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","volume":"181","author":"MK Flynn","year":"2009","unstructured":"Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181(6):2608\u201315. https:\/\/doi.org\/10.1016\/j.juro.2009.01.117.","journal-title":"J Urol"},{"issue":"1","key":"4691_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s1701-2163(15)31049-5","volume":"35","author":"C Jabs","year":"2013","unstructured":"Jabs C, Carleton E. Efficacy of botulinum toxin a intradetrusor injections for non-neurogenic urinary urge incontinence: a randomized double-blind controlled trial. J Obstet Gynaecol Can. 2013;35(1):53\u201360. https:\/\/doi.org\/10.1016\/s1701-2163(15)31049-5.","journal-title":"J Obstet Gynaecol Can"},{"issue":"3","key":"4691_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","volume":"62","author":"DG Tincello","year":"2012","unstructured":"Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol. 2012;62(3):507\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2011.12.056.","journal-title":"Eur Urol"},{"issue":"5","key":"4691_CR16","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","volume":"193","author":"EA Gormley","year":"2015","unstructured":"Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment. J Urol. 2015;193(5):1572\u201380. https:\/\/doi.org\/10.1016\/j.juro.2015.01.087.","journal-title":"J Urol"},{"key":"4691_CR17","unstructured":"Allergan. (2019, October 1). BOTOX Cosmetic (onabotulinumtoxinA) for injection, for intramuscular use. Retrieved May 6, 2020, from https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/20190626-BOTOX-Cosmetic-Insert-72715US10-Med-Guide-v2-0MG1145.pdf"},{"issue":"5","key":"4691_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/SPV.0000000000000112","volume":"20","author":"American Urogynecologic Society and American College of Obstetricians and Gynecologists","year":"2014","unstructured":"American Urogynecologic Society and American College of Obstetricians and Gynecologists. Committee opinion: onabotulinumtoxinA and the bladder. Female Pelvic Med Reconstr Surg. 2014;20(5):245\u20137. https:\/\/doi.org\/10.1097\/SPV.0000000000000112.","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"1","key":"4691_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100\u201319. https:\/\/doi.org\/10.1016\/j.eururo.2008.09.009.","journal-title":"Eur Urol"},{"issue":"4","key":"4691_CR20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.juro.2008.01.068","volume":"179","author":"JS Wolf Jr","year":"2008","unstructured":"Wolf JS Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis [published correction appears in J Urol. 2008 Nov;180(5):2262-3]. J Urol. 2008;179(4):1379\u201390. https:\/\/doi.org\/10.1016\/j.juro.2008.01.068.","journal-title":"J Urol"},{"issue":"2","key":"4691_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JU.0000000000000509","volume":"203","author":"DJ Lightner","year":"2020","unstructured":"Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203(2):351\u20136. https:\/\/doi.org\/10.1097\/JU.0000000000000509.","journal-title":"J Urol"},{"issue":"3","key":"4691_CR22","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/nau.23034","volume":"36","author":"MH Khan","year":"2017","unstructured":"Khan MH, Baldo O, Koenig P, Shaikh N. Use of prophylactic antibiotics for intra-vesicle Botox\u00ae injection. Neurourol Urodyn. 2017;36(3):828. https:\/\/doi.org\/10.1002\/nau.23034.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"4691_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00192-018-3721-4","volume":"30","author":"J Houman","year":"2019","unstructured":"Houman J, Moradzadeh A, Patel DN, Asanad K, Anger JT, Eilber KS. What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens. Int Urogynecol J. 2019;30(5):701\u20134. https:\/\/doi.org\/10.1007\/s00192-018-3721-4.","journal-title":"Int Urogynecol J"},{"key":"4691_CR24","doi-asserted-by":"publisher","first-page":"33197","DOI":"10.1038\/srep33197","volume":"6","author":"L Leitner","year":"2016","unstructured":"Leitner L, Sammer U, Walter M, et al. Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. Sci Rep. 2016;6:33197. Published 2016 Sep 12. https:\/\/doi.org\/10.1038\/srep33197.","journal-title":"Sci Rep"},{"issue":"11","key":"4691_CR25","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/j.1464-410X.2010.09435.x","volume":"106","author":"S Mouttalib","year":"2010","unstructured":"Mouttalib S, Khan S, Castel-Lacanal E, et al. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int. 2010;106(11):1677\u201380. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09435.x.","journal-title":"BJU Int"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-021-04691-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-021-04691-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-021-04691-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T14:04:43Z","timestamp":1646057083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-021-04691-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4691"],"URL":"https:\/\/doi.org\/10.1007\/s00192-021-04691-4","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}